TS
LJPC

Thomas Steyer’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Thomas Steyer’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-257,500
Closed -$7.69M – 102
2017
Q1 		$7.69M Buy
+257,500
New +$6.57M 0.08% 63

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Thomas Steyer's LJPC Position: Q2 2017 in Review

Thomas Steyer sold out of La Jolla Pharmaceutical Company (LJPC) in Q2 2017, closing a stake of 257,500 shares — an estimated $7.69M sold.

Thomas Steyer first reported a position in LJPC in Q1 2017 and held it in 1 quarter. The position peaked at $7.69M in Q1 2017. 83 funds tracked by Wall St. Rank hold LJPC as of Q2 2017.

  • Thomas Steyer reported no remaining La Jolla Pharmaceutical Company position as of Q2 2017 after selling out during the quarter.
  • Thomas Steyer sold 257,500 La Jolla Pharmaceutical Company shares in Q2 2017, an estimated $7.69M.
  • Thomas Steyer first reported a position in La Jolla Pharmaceutical Company in Q1 2017 and held it in 1 quarter.
  • Thomas Steyer's La Jolla Pharmaceutical Company position peaked at $7.69M in Q1 2017.
  • 83 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q2 2017.

Based on Farallon Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.